Safety and Immunogenicity of Q Fever Vaccine

Q Fever Clinical Trial

Official title:
Evaluation of the Safety and Immunogenicity of Q Fever Vaccine, Phase I, Inactivated, Dried, NDBR 105, in Subjects at Risk of Exposure to Coxiella Burnetii

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to evaluate the safety of Q Fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 and collect data on incidence of occupational Q fever infection in vaccinated personnel.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02092142
Study type	Interventional
Source	U.S. Army Medical Research and Development Command
Contact
Status	Withdrawn
Phase	Phase 2
Start date	February 2006
Completion date	December 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03334019` - Prevalence and Risk Factors for Coxiella Burnetii Seropositivity (Q Fever) Among Adults in Western France
Active, not recruiting	`NCT01450501` - Chronic Q-fever in Patients With an Abdominal Aortic Disease (QAAD-study)	N/A
Recruiting	`NCT01095328` - A Screening Strategy for Q Fever Among Pregnant Women	N/A
Completed	`NCT02822807` - Q Fever and Auto-immunity	N/A
Completed	`NCT02898402` - Study on Seroprevalence and Risk Factors of Coxiella Burnetii (Q Fever) in the South of Reunion Island	N/A
Completed	`NCT00584454` - Safety Evaluation of a Q-fever Vaccine, NDBR 105	Phase 2
Completed	`NCT01318356` - The Qure Study: Q-fever Fatigue Syndrome - Response to Treatment	Phase 4